According to a recent LinkedIn post from Infinity Bio Inc, the company is participating in the IMMUNOLOGY2026 conference in Boston and hosting visitors at Booth 418 in the exhibit hall. The post also draws attention to a scientific poster to be presented by team member Katy Shaw-Saliba on April 18, focused on decoding the antibody reactome at scale using novel antigen display technology.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Infinity Bio Inc is actively engaging with the immunology research community and showcasing its capabilities in antibody reactomics and related technologies. For investors, this type of presence at a major scientific meeting may indicate ongoing R&D efforts, potential for academic and industry collaborations, and growing brand visibility in the immunology tools and analytics space.
While the post does not reference specific commercial products, partnerships, or revenue-related milestones, the emphasis on scalable antigen display and immune-history analysis could point to platform technologies with translational or commercial potential. Continued involvement in high-profile conferences may help the company build scientific credibility, support future business development, and position itself within competitive niches such as antibody discovery, biomarker analysis, or immune profiling.